Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Notes Payables (2022 - 2025)

Oramed Pharmaceuticals' Notes Payables history spans 4 years, with the latest figure at $652000.0 for Q4 2025.

  • For Q4 2025, Notes Payables changed N/A year-over-year to $652000.0; the TTM value through Dec 2025 reached $652000.0, changed N/A, while the annual FY2025 figure was $652000.0, N/A changed from the prior year.
  • Notes Payables reached $652000.0 in Q4 2025 per ORMP's latest filing, up from $1000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $75.4 million in Q3 2023 to a low of $1000.0 in Q2 2022.
  • Average Notes Payables over 4 years is $8.4 million, with a median of $35000.0 recorded in 2024.
  • The largest YoY upside for Notes Payables was 3203300.0% in 2024 against a maximum downside of 99.95% in 2024.
  • A 4-year view of Notes Payables shows it stood at $1000.0 in 2022, then surged by 32400.0% to $325000.0 in 2023, then plummeted by 89.23% to $35000.0 in 2024, then skyrocketed by 1762.86% to $652000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Notes Payables are $652000.0 (Q4 2025), $1000.0 (Q3 2025), and $34000.0 (Q2 2025).